EQL PHARMA AB (7JK) — Financial Flexibility Index
EQL PHARMA AB (7JK) has a Financial Flexibility Index of 0.06x as of March 2026. Free cash flow of €34.01 Million (operating CF €16.79 Million minus capex €17.22 Million) represents 0% of total liabilities (€583.83 Million). Check 7JK cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
EQL PHARMA AB Financial Flexibility Index (2022–2026)
Historical Financial Flexibility Index trend for EQL PHARMA AB across 5 annual periods. For the full cash flow conversion analysis, see EQL PHARMA AB (7JK) cash conversion ratio.
Annual Financial Flexibility Index for EQL PHARMA AB (2022–2026)
Year-by-year free cash flow to debt coverage for EQL PHARMA AB. Explore EQL PHARMA AB debt service capacity to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2026 | 0.16x | €95.60 Million | €28.36 Million | €583.83 Million | ▼ -56.5% |
| 2025 | 0.38x | €221.19 Million | €-24.65 Million | €587.79 Million | ▲ +34.6% |
| 2024 | 0.28x | €54.83 Million | €-11.44 Million | €196.03 Million | ▼ -23.9% |
| 2023 | 0.37x | €48.12 Million | €27.62 Million | €130.94 Million | ▼ -34.3% |
| 2022 | 0.56x | €63.92 Million | €41.83 Million | €114.26 Million | — |